Accuracy of Fibrosis-4 index and non-alcoholic fatty liver disease fibrosis scores in metabolic (dysfunction) associated fatty liver disease according to body mass index: failure in the prediction of advanced fibrosis in lean and morbidly obese individuals.

Creative Commons License

Eren F., Kaya E., Yilmaz Y.

European journal of gastroenterology & hepatology, cilt.34, ss.98-103, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 34
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1097/meg.0000000000001946
  • Dergi Adı: European journal of gastroenterology & hepatology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, CINAHL, EMBASE, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.98-103
  • Anahtar Kelimeler: fibrosis, metabolic (dysfunction) associated fatty liver disease, non-invasive scores, screening, NAFLD, STIFFNESS, OUTCOMES, SYSTEM, STAGE
  • Marmara Üniversitesi Adresli: Evet

Özet

Background and aim While non-invasive scores are increasingly being used to screen for advanced fibrosis in

metabolic (dysfunction) associated fatty liver disease (MAFLD), the effect of BMI on their clinical utility remains uncertain. This

study assessed the usefulness of the Fibrosis-4 index (FIB-4) and the non-alcoholic fatty liver disease fibrosis score (NFS) in

lean, overweight, obese, severely obese, and morbidly obese patients with biopsy-proven MAFLD.

Methods A total of 560 patients (28 lean, 174 overweight, 229 obese, 89 severely obese, 40 morbidly obese) were included.

Diagnostic performances and optimal cut-off values for FIB-4 and NFS were calculated using receiver operating characteristic

(ROC) curve analysis.

Results In both lean and morbidly obese patients with MAFLD, both FIB-4 and NFS failed to discriminate advanced fibrosis.

Conversely, both scores showed acceptable diagnostic performances in exclusion of advanced fibrosis in overweight,

obese, and severely obese patients. FIB-4 was able to exclude advanced fibrosis with the highest diagnostic accuracy in the

subgroup of overweight patients (area under the ROC curve: 0.829, 95% confidence interval: 0.738−0.919).

Conclusion FIB-4 and NFS can confidently be used to exclude advanced fibrosis in overweight, obese, and severely obese

patients. However, they do not appear clinically useful in lean and morbidly obese patients.